Amylin receptor (AMY) (AMY)

The amylin receptor is a functional heterodimeric complex formed by the association of the calcitonin receptor (CTR), a Class B G protein-coupled receptor, with one of three receptor activity-modifying proteins: RAMP1, RAMP2, or RAMP3 (Bower & Hay, 2016, British Journal of Pharmacology). These complexes, known as AMY1, AMY2, and AMY3 respectively, are the primary mediators of the physiological actions of amylin, a hormone co-secreted with insulin from pancreatic beta cells (Lutz, 2010, Molecular Metabolism). Located predominantly in the area postrema of the hindbrain, these receptors play a crucial role in energy balance by inducing satiety, slowing gastric emptying, and suppressing postprandial glucagon secretion (Hay et al., 2015, Pharmacological Reviews). In clinical practice, the amylin receptor is a validated therapeutic target for metabolic diseases; for instance, the synthetic analogue pramlintide is FDA-approved for treating type 1 and type 2 diabetes (Young, 2005, Advances in Pharmacology). Furthermore, long-acting amylin receptor agonists like cagrilintide are currently under intensive investigation for the treatment of obesity due to their potent weight-loss effects (Frias et al., 2021, The Lancet). Beyond metabolic regulation, the calcitonin receptor component of these complexes also participates in calcium homeostasis and the inhibition of bone resorption by osteoclasts (Naot & Cornish, 2008, Bone).

Other names

Calcitonin receptor/RAMP complexAMY1AMY2AMY3CTR/RAMP complexCalcitonin receptor-receptor activity-modifying protein complexCALCR/RAMP complex

Amylin receptor agonism